Sanfilippo Gene Therapy Gains FDA Approval
World Sanfilippo Day spotlights a rare, fatal neurodegenerative disease that families say is often mistaken for childhood Alzheimer's.
Updated on Nov. 16, 2026 in Alzheimer’s

World Sanfilippo Day drew attention to Sanfilippo syndrome, a rare neurodegenerative disease. The FDA approved Fayuvi, a gene therapy infusion for Sanfilippo type A, in September 2026.
Why it matters
Sanfilippo syndrome is caused by a missing or malfunctioning enzyme that disrupts the brain's ability to break down waste sugars, and the approval offers a first targeted treatment option for the most severe subtype. Families note the therapy stabilizes progression but does not reverse existing damage.
The FDA approval of Fayuvi in September 2026 is a regulatory milestone, though the source reports no trial efficacy percentages or patient counts. The Walline family's $2.5 million fundraising goal by Christmas Eve remains unresolved in the source.
The players
Cure Sanfilippo Foundation
A nonprofit organization focused on research and advocacy for families affected by Sanfilippo syndrome.
NeuroGT
A company running a clinical trial for Sanfilippo type B scheduled to begin in January.
The details
Sanfilippo syndrome stems from genetic defects that disrupt production of enzymes needed to break down waste sugars in the brain, causing progressive loss of cognitive function, including previously acquired speech. The Cure Sanfilippo Foundation identifies type A as the most severe subtype, which includes types A, B, C and D.
Timeline
September 2026: FDA approved Fayuvi, a gene therapy infusion for Sanfilippo type A.
2025: Elle Walline was diagnosed with Sanfilippo type C.
January 2027: A NeuroGT clinical trial for Sanfilippo type B is scheduled to start.
Christmas Eve 2026: Deadline for the Walline family's $2.5 million fundraising goal.
Big Picture
The FDA's September 2026 approval of Fayuvi, a gene therapy for Sanfilippo type A, marks the first gene-based option for this subtype. The treatment stabilizes progression but does not reverse damage already done, placing it as a disease-management step rather than a cure.
Families of children with Sanfilippo type A may now have access to a gene therapy that slows progression, though it does not reverse existing damage. The approval affects treatment decisions for diagnosed children and their caregivers.
The takeaway
Early diagnosis matters for Sanfilippo syndrome because therapies work best before significant neurological damage occurs. Parents who notice developmental regression in young children should raise it with a pediatric neurologist promptly.
What happens next
A NeuroGT clinical trial for Sanfilippo type B is scheduled to start in January 2027.
Further reading
Explore related coverage in the Alzheimer’s section for context on childhood neurodegenerative conditions.






